Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis-Reference-Cited by-同舟云学术

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis

Published:2021-04-19 Issue:12 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Sbidian Emilie¹²³,Chaimani Anna⁴⁵,Garcia-Doval Ignacio⁶,Doney Liz⁷,Dressler Corinna⁸,Hua Camille¹³,Hughes Carolyn⁹,Naldi Luigi¹⁰,Afach Sivem³,Le Cleach Laurence¹³

Affiliation:

1. Department of Dermatology; Hôpital Henri Mondor; Créteil France

2. Clinical Investigation Centre; Hôpital Henri Mondor; Créteil France

3. Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) - EA 7379; Université Paris Est Créteil (UPEC); Créteil France

4. Université de Paris, Centre of Research in Epidemiology and Statistics (CRESS), INSERM, F-75004; Paris France

5. Cochrane France; Paris France

6. Department of Dermatology; Complexo Hospitalario Universitario de Vigo; Vigo Spain

7. Cochrane Skin, Centre of Evidence Based Dermatology; University of Nottingham; Nottingham UK

8. Division of Evidence Based Medicine, Department of Dermatology, Venerology and Allergology; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Berlin Germany

9. c/o Cochrane Skin Group; The University of Nottingham; Nottingham UK

10. Centro Studi GISED (Italian Group for Epidemiologic Research in Dermatology) - FROM (Research Foundation of Ospedale Maggiore Bergamo); Padiglione Mazzoleni - Presidio Ospedaliero Matteo Rota; Bergamo Italy

Publisher

Wiley

Subject

Pharmacology (medical)

Reference943 articles.

1. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis;Griffiths;New England Journal of Medicine,2010

2. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients;Young;Expert Review of Clinical Immunology,2011

3. Long-term efficacy, safety, and immunogenicity data from a phase iii confirmatory study comparing GP2017, a proposed biosimilar, with reference adalimumab;Blauvelt;United European Gastroenterology Journal,2017

4. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches;Blauvelt;British Journal of Dermatology,2018

5. Study to demonstrate equivalent efficacy and to compare safety of biosimilar adalimumab (GP2017) and humira (ADACCESS) clinicaltrials.gov/show/nct02016105

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study;European Journal of Pharmacology;2024-01

2. Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan;Dermatology and Therapy;2023-11-29

3. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis;Drug Safety;2023-10-31

4. Comparing Meta-Analyses with ChatGPT in the Evaluation of the Effectiveness and Tolerance of Systemic Therapies in Moderate-to-Severe Plaque Psoriasis;Journal of Clinical Medicine;2023-08-20

5. Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies – Adult patients;Australasian Journal of Dermatology;2023-07-28